



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

20th August, 2021

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

A handwritten signature in black ink that reads "M. Adinarayana".

M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 13 /2021-22

Press Release

20th August, 2021

Legal update on Ibrutinib

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces that a US District Court has issued a decision in favour of Pharmacyclics (a subsidiary of AbbVie), the brand owner of Imbruvica[®] in a PIV litigation involving the product.

NATCO and its marketing partner in US for the product, Alvogen Pine Brook LLC, USA, shall review the judgement and evaluate all options to appeal the judgement. We believe that we have a strong case and will continue to defend vigorously.

In the year 2018 NATCO and Alvogen, have filed an Abbreviated New Drug Application (ANDA) with PIV certification for generic version of the product.

*All brand names and trademarks are the property of their respective owners

Forwarded for favor of publication

For NATCO Pharma Limited

A handwritten signature in black ink that reads "M Adinarayana".

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)